Antibody Ingredients TRIZ Cases

Antibodies target the CLD18A2 isoform to destroy tumor cells while sparing normal tissue, resolving the trade-off between therapeutic efficacy and side effects.

Anti-polyphosphate antibodies neutralize polyphosphates, resolving therapy delays in sepsis treatment.

Removing light chains simplifies manufacturing while maintaining high affinity against BCMA.

Radiolabeled HER3 targeting agents deliver DNA-damaging ionizing radiation to overcome dose-dependent receptor downregulation in solid tumors.

Humanized anti-FasL antibodies block Fas ligand interactions to inhibit keratinocyte apoptosis in autoimmune skin conditions.

Engineered VNAR polypeptides target TfR-1 to deliver drugs across the blood-brain barrier, reducing required doses and minimizing adverse side effects.

Removing the Fc region from agonistic CD40 antibodies prevents toxic cytokine release syndromes while maintaining robust cellular immune responses.

Dynamic dose adjustment using breakthrough event feedback resolves the contradiction between therapeutic efficacy and adverse events in cancer immunotherapy.

Mutating light chain CDR3 aspartic acid to asparagine or glutamic acid in panitumumab variants.

A CBP/catenin inhibitor reduces beta-catenin expression to promote T cell infiltration, overcoming low sensitivity in high beta-catenin tumors.

Monoclonal antibody binds CD26 on T lymphocytes to treat GvHD and Aplastic Anemia.

A bispecific dimer combines anti-PD-L1 and anti-CTLA4 binding domains into a single molecule to block two immune checkpoints simultaneously.

Humanized IgG2 antibodies bind specific epitopes on activated protein C to selectively inhibit anticoagulant activity while preserving cytoprotective functions.

TREM-1 antibodies block receptor activation to resolve agonistic activity and enable primate cross-reactivity for toxicology studies.

Fully human antibodies targeting LAG3 reduce immunogenicity while maintaining binding affinity and cross-reactivity to improve therapeutic efficacy.

Primed anti-CD47 dosing overcomes rituximab refractoriness by blocking inhibitory signals to enhance phagocytosis.

Agonistic anti-TNFR2 antibodies activate receptor signaling without blocking TNF-alpha binding.

Modified heavy chain constant regions enhance antibody internalization and biological activity through targeted structural mutations.

Segmented antibody-drug conjugates resolve low therapeutic effectiveness by delivering cytotoxic payloads directly to NTB-A-expressing cancer cells.

FRα-specific antibodies detect folate receptor alpha concentrations, enabling early diagnosis of FRα-expressing cancers.

Antibodies bind the N-terminal region of tissue factor pathway inhibitor to neutralize its inhibitory effects on coagulation complexes.

Targeted Fc modifications and afucosylation enhance ADCC and CDC activities to overcome multiple myeloma relapse risks.

Depleting CD205+ immune modulatory cells with antibody conjugates removes tumor suppression and boosts checkpoint inhibitor efficacy.

Combines tumor-associated antigen antibodies with immune activators to localize reactions and reduce systemic side effects.

Anti-human OX40L antibodies block receptor interactions to decrease cytokine secretion and leukocyte proliferation in graft versus host disease.

Asymmetric bispecific antibody redirects cytotoxicity to CD1a-expressing T-ALL cells while avoiding non-specific activation of healthy immune cells.

Talquetamab-tgvs employs step-up dosing and REMS programs to manage cytokine release syndrome while treating relapsed multiple myeloma.

Targeting MIGIS-alpha on B cells reduces inflammation without broad immunosuppression, addressing safety risks in IgA nephropathy treatment.

A monoclonal antibody binds the IL13Rα2 receptor to block IL-13 signaling and promote receptor degradation.

Local quality detection of viral markers guides anti-CD73 antibody therapy to relieve immunosuppression in oncovirus-positive cancers.

Elbow hinge mutations alter antibody orientation to modulate direct cell death induction without compromising structural stability.

Adjusting culture medium glucose levels controls high mannose Fab glycoform consistency, reducing antibody clearance rates and improving bioavailability.

Non-fucosylated variant antigen binding molecule targets membrane-bound CEA while avoiding serum interference to improve clinical effectiveness.

Combining anti-PD-1 antibodies with anti-CD30 antibody-drug conjugates modulates immune responses against solid tumors.

Antibody agonists bind to NaK ATPase subunits to restore calcium homeostasis and prevent life-threatening arrhythmia.

Heterodimeric antibodies bind CD28 on T cells and B7H3 on tumors, enhancing anti-tumor activity while minimizing peripheral toxicity.

Combining a PD-L1 binding antagonist with an anti-CEA/anti-CD3 bispecific antibody enhances CD8+ T cell-mediated tumor killing.

Engineered human monoclonal antibodies bind mesothelin with high affinity, enabling internalization and ADCC to treat mesotheliomas.

Novel humanized monoclonal antibodies bind specific Microfibrillar-associated protein 4 epitopes with enhanced stability.

Targeted antibodies inhibit tumor metastasis by blocking ENO1-plasminogen interaction, preventing extracellular matrix degradation and cancer cell dissociation.

Decapping Cys80 in light chain variable regions enables precise thiol-reactive compound attachment, resolving heterogeneity from lysine conjugation.

Fully human monoclonal antibodies bind 4-1BB to modulate immune responses and enhance T cell proliferation.

EBV immortalizes human B-cells to produce nucleolin-specific antibodies, eliminating serum sickness from animal-derived immunogens.

Humanized antibodies targeting GD2 and GD3 gangliosides reduce pain and neuropathy side effects while maintaining therapeutic index.

CyTaCs bridge target antigens and immune effectors, resolving manufacturing complexity while maintaining selectivity.

Merging costimulatory agonist and checkpoint inhibitor functions into one molecule overcomes limited response rates of monotherapy.

Combining CEAxCD28 bispecific antibodies with PD-1 blockers overcomes limited solid cancer efficacy by enhancing in vivo anti-tumoral activity.

UniTEA bispecific antibody links CD3 and organic fluorophore to overcome antigen escape and tumor heterogeneity in cancer therapy.

Anti-CD47 antibodies block SIRPα interactions to trigger macrophage-mediated phagocytosis of tumor cells.